Literature DB >> 9869273

Comparative study of [3H]ramosetron and [3H]granisetron binding in the cloned human 5-hydroxytryptamine3 receptors.

S Akuzawa1, H Ito, T Yamaguchi.   

Abstract

Characteristics of the binding of [3H]ramosetron to cloned human 5-hydroxytryptamine3 (5-HT3) receptors were investigated and directly compared to those of [3H]granisetron binding. Saturation studies revealed that [3H]ramosetron labeled more sites with high affinity (Kd=0.15+/-0.01 nM, Bmax =653 +/- 30 fmol/mg protein) than [3H]granisetron (Kd=1.17+/-0.25 nM, Bmax=427+/-43 fmol/mg protein). Kinetic studies revealed that dissociation of [3H]ramosetron was slower than that of [3H]granisetron. These results suggest that ramosetron is a highly potent 5-HT3-receptor antagonist.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9869273     DOI： 10.1254/jjp.78.381

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN： 0021-5198


  6 in total

Review 1.  The 5-HT3 receptor as a therapeutic target.

Authors:  Andrew J Thompson; Sarah C R Lummis
Journal:  Expert Opin Ther Targets       Date:  2007-04       Impact factor: 6.902

2.  Effect of ramosetron, a 5-HT3 receptor antagonist on the severity of seizures and memory impairment in electrical amygdala kindled rats.

Authors:  Zeynab Sayahi; Alireza Komaki; Masoud Saidi Jam; Seyed Asaad Karimi; Safoura Raoufi; Parastoo Mardani; Marzieh Naderishahab; Abdolrahman Sarihi; Javad Mirnajafi-Zadeh
Journal:  J Physiol Sci       Date:  2022-01-16       Impact factor: 2.781

3.  Comparison of ramosetron with ondansetron for the prevention of post-operative nausea and vomiting in high-risk patients.

Authors:  Sandip Agarkar; Aparna S Chatterjee
Journal:  Indian J Anaesth       Date:  2015-04

4.  A Randomised Controlled Trial to Compare the Effect of Ramosetron and Ondansetron in Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gynaecological Procedures.

Authors:  Sashmita Das; Anil Kumar; Anshu Gupta; Ajai Kumar
Journal:  Cureus       Date:  2022-09-15

5.  Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome.

Authors:  Toshimi Chiba; Kazunari Yamamoto; Shoko Sato; Kazuyuki Suzuki
Journal:  Clin Exp Gastroenterol       Date:  2013-07-25

6.  Effect of total intravenous anaesthesia and prophylactic ramosetron on postoperative nausea and vomiting after thyroidectomy: A prospective, randomized controlled study.

Authors:  Han Bum Joe; Sook Young Lee; Jin-Soo Kim; Hyuk Soo Chang; Yunyong Jeong; Haewon Jeong; Sung Yong Park
Journal:  J Int Med Res       Date:  2015-12-10       Impact factor: 1.671
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.